Kathleen Victoria Fitch, M.S.N.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 86 | 2024 | 17165 | 3.200 |
Why?
|
Plaque, Atherosclerotic | 17 | 2024 | 1518 | 1.600 |
Why?
|
Coronary Artery Disease | 22 | 2024 | 6659 | 1.190 |
Why?
|
Cardiovascular Diseases | 23 | 2024 | 15757 | 1.040 |
Why?
|
HIV | 12 | 2023 | 1579 | 1.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2024 | 3334 | 0.900 |
Why?
|
Sweetening Agents | 2 | 2022 | 290 | 0.850 |
Why?
|
Quinolines | 8 | 2024 | 759 | 0.750 |
Why?
|
Atherosclerosis | 9 | 2024 | 3517 | 0.690 |
Why?
|
Life Style | 5 | 2019 | 3896 | 0.690 |
Why?
|
Diet Therapy | 1 | 2019 | 151 | 0.630 |
Why?
|
Amino Acids | 3 | 2020 | 1714 | 0.630 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 5 | 2021 | 138 | 0.560 |
Why?
|
Multicenter Studies as Topic | 3 | 2020 | 1722 | 0.540 |
Why?
|
Monocytes | 4 | 2018 | 2575 | 0.490 |
Why?
|
Renin-Angiotensin System | 6 | 2022 | 738 | 0.480 |
Why?
|
Bone Diseases | 2 | 2019 | 419 | 0.430 |
Why?
|
Fibrosis | 2 | 2018 | 2042 | 0.420 |
Why?
|
Inflammation | 16 | 2024 | 10756 | 0.410 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 5 | 2018 | 282 | 0.410 |
Why?
|
Adiposity | 7 | 2021 | 1858 | 0.400 |
Why?
|
Tunica Media | 2 | 2011 | 112 | 0.390 |
Why?
|
Middle Aged | 75 | 2024 | 220352 | 0.380 |
Why?
|
Nutrition Disorders | 1 | 2011 | 205 | 0.370 |
Why?
|
Dyslipidemias | 3 | 2019 | 895 | 0.360 |
Why?
|
Asymptomatic Diseases | 5 | 2018 | 587 | 0.360 |
Why?
|
Patient Selection | 2 | 2020 | 4283 | 0.350 |
Why?
|
Subcutaneous Fat | 5 | 2019 | 393 | 0.350 |
Why?
|
Tunica Intima | 2 | 2011 | 459 | 0.330 |
Why?
|
Intra-Abdominal Fat | 4 | 2019 | 608 | 0.320 |
Why?
|
Aging | 3 | 2020 | 8651 | 0.310 |
Why?
|
Fingers | 1 | 2011 | 506 | 0.300 |
Why?
|
Metformin | 2 | 2014 | 912 | 0.300 |
Why?
|
Arteritis | 2 | 2022 | 162 | 0.300 |
Why?
|
Adipose Tissue | 6 | 2023 | 3301 | 0.290 |
Why?
|
Diet | 4 | 2022 | 8010 | 0.290 |
Why?
|
Neck | 2 | 2016 | 731 | 0.290 |
Why?
|
Adipose Tissue, Brown | 4 | 2019 | 755 | 0.280 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 831 | 0.280 |
Why?
|
Ribonuclease III | 2 | 2021 | 279 | 0.280 |
Why?
|
Anti-Retroviral Agents | 6 | 2023 | 1779 | 0.280 |
Why?
|
Anti-HIV Agents | 9 | 2020 | 4491 | 0.280 |
Why?
|
Male | 72 | 2024 | 359744 | 0.280 |
Why?
|
Carotid Arteries | 1 | 2011 | 951 | 0.270 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 223 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10344 | 0.260 |
Why?
|
DEAD-box RNA Helicases | 2 | 2021 | 383 | 0.260 |
Why?
|
Female | 72 | 2024 | 391270 | 0.260 |
Why?
|
Humans | 97 | 2024 | 760621 | 0.250 |
Why?
|
Calcinosis | 2 | 2012 | 1476 | 0.250 |
Why?
|
Body Composition | 12 | 2019 | 2419 | 0.250 |
Why?
|
Drug Resistance, Viral | 2 | 2023 | 859 | 0.240 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 1109 | 0.240 |
Why?
|
Adult | 47 | 2023 | 219994 | 0.240 |
Why?
|
Risk Factors | 23 | 2024 | 74359 | 0.240 |
Why?
|
Receptors, Cell Surface | 5 | 2018 | 2825 | 0.230 |
Why?
|
HIV Integrase Inhibitors | 2 | 2023 | 165 | 0.220 |
Why?
|
Lipoproteins, LDL | 4 | 2024 | 641 | 0.220 |
Why?
|
Viral Load | 8 | 2022 | 3322 | 0.220 |
Why?
|
Antigens, CD | 5 | 2018 | 4000 | 0.220 |
Why?
|
Nutritional Status | 1 | 2011 | 1607 | 0.220 |
Why?
|
Exercise | 1 | 2019 | 5787 | 0.210 |
Why?
|
Insulin Resistance | 6 | 2021 | 3959 | 0.210 |
Why?
|
Sex Factors | 7 | 2019 | 10547 | 0.210 |
Why?
|
Body Mass Index | 10 | 2023 | 12914 | 0.210 |
Why?
|
HIV Integrase | 1 | 2023 | 121 | 0.200 |
Why?
|
Blood Proteins | 3 | 2023 | 1173 | 0.190 |
Why?
|
Subcutaneous Fat, Abdominal | 2 | 2019 | 91 | 0.180 |
Why?
|
Hepacivirus | 1 | 2018 | 1334 | 0.180 |
Why?
|
HIV-1 | 6 | 2023 | 6849 | 0.180 |
Why?
|
HIV Long-Term Survivors | 1 | 2020 | 121 | 0.170 |
Why?
|
Proteomics | 4 | 2023 | 3817 | 0.170 |
Why?
|
Hyperinsulinism | 2 | 2017 | 402 | 0.170 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2019 | 34 | 0.160 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 3150 | 0.160 |
Why?
|
Prevalence | 7 | 2022 | 15687 | 0.160 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 4433 | 0.160 |
Why?
|
Serum | 2 | 2019 | 211 | 0.160 |
Why?
|
Absorptiometry, Photon | 2 | 2019 | 1736 | 0.160 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 25942 | 0.150 |
Why?
|
Comorbidity | 5 | 2020 | 10551 | 0.150 |
Why?
|
Research Subjects | 1 | 2020 | 249 | 0.150 |
Why?
|
Coronary Angiography | 6 | 2024 | 4563 | 0.150 |
Why?
|
Young Adult | 15 | 2021 | 58741 | 0.150 |
Why?
|
Heart Diseases | 1 | 2011 | 2809 | 0.150 |
Why?
|
Methylamines | 2 | 2016 | 138 | 0.150 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 407 | 0.150 |
Why?
|
Hepatitis C | 1 | 2018 | 1579 | 0.150 |
Why?
|
Cholesterol, LDL | 5 | 2024 | 2420 | 0.140 |
Why?
|
Natriuretic Peptides | 1 | 2018 | 156 | 0.140 |
Why?
|
Tomography, X-Ray | 1 | 2016 | 60 | 0.140 |
Why?
|
Angiography | 3 | 2016 | 1605 | 0.130 |
Why?
|
CD4 Lymphocyte Count | 5 | 2020 | 2569 | 0.130 |
Why?
|
Food Supply | 1 | 2022 | 542 | 0.130 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2022 | 618 | 0.130 |
Why?
|
Adolescent | 18 | 2021 | 87810 | 0.130 |
Why?
|
Smoking | 1 | 2013 | 9073 | 0.130 |
Why?
|
Muscle Cells | 1 | 2016 | 195 | 0.130 |
Why?
|
Sodium | 2 | 2022 | 1594 | 0.130 |
Why?
|
Triglycerides | 3 | 2020 | 2476 | 0.130 |
Why?
|
Antiviral Agents | 1 | 2018 | 3061 | 0.120 |
Why?
|
Double-Blind Method | 8 | 2024 | 12427 | 0.120 |
Why?
|
Macrophage Activation | 1 | 2018 | 554 | 0.120 |
Why?
|
Pravastatin | 1 | 2017 | 393 | 0.120 |
Why?
|
Nutrition Policy | 1 | 2019 | 470 | 0.120 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 2180 | 0.120 |
Why?
|
Diet Surveys | 1 | 2019 | 1161 | 0.120 |
Why?
|
Aged | 20 | 2023 | 169152 | 0.120 |
Why?
|
Gender Identity | 1 | 2020 | 698 | 0.120 |
Why?
|
Coronary Vessels | 4 | 2023 | 3112 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2020 | 1175 | 0.120 |
Why?
|
Behavior Therapy | 1 | 2019 | 868 | 0.110 |
Why?
|
International Cooperation | 1 | 2020 | 1433 | 0.110 |
Why?
|
Regression Analysis | 3 | 2013 | 6360 | 0.110 |
Why?
|
Cholesterol, HDL | 2 | 2013 | 1817 | 0.110 |
Why?
|
Blood Coagulation Disorders | 1 | 2016 | 349 | 0.110 |
Why?
|
Pericardium | 1 | 2018 | 675 | 0.110 |
Why?
|
Adipose Tissue, White | 1 | 2016 | 365 | 0.110 |
Why?
|
Minority Groups | 1 | 2020 | 1201 | 0.100 |
Why?
|
Boston | 2 | 2019 | 9280 | 0.100 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 316 | 0.100 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 129 | 0.100 |
Why?
|
Menopause | 1 | 2020 | 1640 | 0.100 |
Why?
|
Anticholesteremic Agents | 2 | 2017 | 987 | 0.100 |
Why?
|
Sex Characteristics | 2 | 2023 | 2629 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 7 | 2019 | 20509 | 0.090 |
Why?
|
Fenofibrate | 1 | 2011 | 88 | 0.090 |
Why?
|
Cardiovascular System | 1 | 2018 | 850 | 0.090 |
Why?
|
Fibronectins | 1 | 2014 | 722 | 0.090 |
Why?
|
Case-Control Studies | 7 | 2020 | 22053 | 0.090 |
Why?
|
Niacin | 1 | 2011 | 119 | 0.090 |
Why?
|
Proteome | 1 | 2020 | 1855 | 0.090 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 1928 | 0.090 |
Why?
|
Intestinal Diseases | 1 | 2015 | 506 | 0.090 |
Why?
|
Iodide Peroxidase | 1 | 2012 | 294 | 0.090 |
Why?
|
Prospective Studies | 8 | 2022 | 54303 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 321 | 0.090 |
Why?
|
Osteoporosis | 1 | 2019 | 1600 | 0.090 |
Why?
|
Hyperemia | 1 | 2011 | 221 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3361 | 0.080 |
Why?
|
North America | 2 | 2024 | 1284 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6498 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1379 | 0.080 |
Why?
|
Cytomegalovirus | 2 | 2024 | 755 | 0.080 |
Why?
|
Calorimetry, Indirect | 1 | 2009 | 174 | 0.080 |
Why?
|
Mass Spectrometry | 1 | 2016 | 2192 | 0.080 |
Why?
|
Primary Prevention | 3 | 2023 | 1207 | 0.080 |
Why?
|
Manometry | 1 | 2011 | 453 | 0.080 |
Why?
|
Fibroblast Growth Factors | 1 | 2014 | 869 | 0.080 |
Why?
|
Blood Pressure | 4 | 2018 | 8525 | 0.080 |
Why?
|
Lipodystrophy | 2 | 2006 | 148 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1952 | 0.080 |
Why?
|
Blood Glucose | 3 | 2021 | 6381 | 0.080 |
Why?
|
Antibodies, Viral | 3 | 2024 | 3143 | 0.070 |
Why?
|
Patient Participation | 1 | 2017 | 1439 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2017 | 1588 | 0.070 |
Why?
|
Stavudine | 1 | 2007 | 84 | 0.070 |
Why?
|
Extremities | 1 | 2012 | 867 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2012 | 2007 | 0.070 |
Why?
|
Adipogenesis | 2 | 2021 | 358 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2290 | 0.070 |
Why?
|
Hyperlipidemias | 1 | 2011 | 782 | 0.070 |
Why?
|
Mitochondria, Muscle | 1 | 2007 | 172 | 0.060 |
Why?
|
Hypertension | 2 | 2019 | 8594 | 0.060 |
Why?
|
Liver | 2 | 2021 | 7509 | 0.060 |
Why?
|
Energy Metabolism | 3 | 2016 | 2869 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2018 | 65017 | 0.060 |
Why?
|
Immunity | 1 | 2011 | 998 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3790 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2924 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3291 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 861 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3696 | 0.060 |
Why?
|
Health Promotion | 1 | 2017 | 2206 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3465 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2019 | 12766 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18416 | 0.060 |
Why?
|
Chemokine CCL2 | 2 | 2017 | 605 | 0.060 |
Why?
|
Heart | 1 | 2017 | 4393 | 0.060 |
Why?
|
Back | 2 | 2016 | 64 | 0.060 |
Why?
|
Aldosterone | 2 | 2022 | 868 | 0.060 |
Why?
|
Exercise Therapy | 1 | 2011 | 919 | 0.060 |
Why?
|
Diet, Sodium-Restricted | 2 | 2016 | 291 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2477 | 0.060 |
Why?
|
Body Size | 1 | 2006 | 462 | 0.060 |
Why?
|
Glucose Clamp Technique | 2 | 2018 | 263 | 0.050 |
Why?
|
Waist Circumference | 2 | 2019 | 926 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2006 | 755 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4122 | 0.050 |
Why?
|
United States | 5 | 2023 | 72461 | 0.050 |
Why?
|
Lipids | 2 | 2018 | 3336 | 0.050 |
Why?
|
Eating | 1 | 2009 | 1539 | 0.050 |
Why?
|
Nucleosides | 1 | 2022 | 131 | 0.050 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2021 | 24 | 0.050 |
Why?
|
Latent TGF-beta Binding Proteins | 1 | 2021 | 43 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5496 | 0.050 |
Why?
|
Treatment Failure | 1 | 2018 | 2648 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2024 | 4541 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 24123 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5889 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 377 | 0.050 |
Why?
|
Obesity | 2 | 2022 | 12922 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2020 | 114 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.050 |
Why?
|
Obesity, Abdominal | 2 | 2015 | 374 | 0.040 |
Why?
|
Receptors, Purinergic P2X5 | 1 | 2019 | 6 | 0.040 |
Why?
|
Muscle, Skeletal | 2 | 2023 | 4925 | 0.040 |
Why?
|
Integrases | 1 | 2022 | 516 | 0.040 |
Why?
|
Reproduction | 2 | 2020 | 646 | 0.040 |
Why?
|
Ultrasonography | 2 | 2011 | 5961 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1843 | 0.040 |
Why?
|
Amino Acid Transport Systems, Neutral | 1 | 2019 | 39 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8803 | 0.040 |
Why?
|
Dietary Fats | 1 | 2007 | 1992 | 0.040 |
Why?
|
Glucose | 2 | 2012 | 4351 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2021 | 251 | 0.040 |
Why?
|
Positron-Emission Tomography | 2 | 2012 | 6465 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4107 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1581 | 0.040 |
Why?
|
Phenotype | 1 | 2016 | 16546 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12159 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2021 | 606 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 41335 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2019 | 432 | 0.040 |
Why?
|
Receptors, Interleukin-1 | 1 | 2018 | 261 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 437 | 0.040 |
Why?
|
Transsexualism | 1 | 2020 | 177 | 0.030 |
Why?
|
Symporters | 1 | 2019 | 361 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2022 | 805 | 0.030 |
Why?
|
Hormones | 2 | 2014 | 867 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2020 | 1894 | 0.030 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2018 | 196 | 0.030 |
Why?
|
Galectin 3 | 1 | 2018 | 240 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2021 | 1343 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 532 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1575 | 0.030 |
Why?
|
Galectins | 1 | 2018 | 282 | 0.030 |
Why?
|
Malnutrition | 1 | 2022 | 640 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7588 | 0.030 |
Why?
|
Gene Silencing | 1 | 2021 | 1513 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2020 | 3765 | 0.030 |
Why?
|
Adipocytes | 1 | 2021 | 1179 | 0.030 |
Why?
|
Body Fat Distribution | 1 | 2016 | 243 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2017 | 1175 | 0.030 |
Why?
|
Down-Regulation | 1 | 2021 | 2913 | 0.030 |
Why?
|
Genotype | 1 | 2018 | 12960 | 0.030 |
Why?
|
Choline | 1 | 2015 | 513 | 0.030 |
Why?
|
Income | 1 | 2021 | 1875 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2016 | 1544 | 0.030 |
Why?
|
Angiotensin II | 1 | 2015 | 849 | 0.030 |
Why?
|
Community Health Services | 1 | 2017 | 654 | 0.020 |
Why?
|
Placebos | 1 | 2016 | 1668 | 0.020 |
Why?
|
RNA, Viral | 1 | 2020 | 2838 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2298 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3711 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1871 | 0.020 |
Why?
|
Drug Interactions | 1 | 2015 | 1428 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1791 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1634 | 0.020 |
Why?
|
Abdominal Fat | 1 | 2012 | 223 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 2981 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2020 | 2062 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2023 | 4353 | 0.020 |
Why?
|
Hypertrophy | 1 | 2012 | 555 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1081 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 12293 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2022 | 3598 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1557 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3849 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2021 | 4938 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2018 | 3215 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2012 | 2262 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4081 | 0.020 |
Why?
|
Body Constitution | 1 | 2007 | 273 | 0.020 |
Why?
|
Atrophy | 1 | 2012 | 1627 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2315 | 0.020 |
Why?
|
Phosphocreatine | 1 | 2007 | 261 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 14372 | 0.020 |
Why?
|
Phosphorus | 1 | 2007 | 333 | 0.020 |
Why?
|
Carotid Artery, Common | 1 | 2006 | 177 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 6180 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11481 | 0.010 |
Why?
|
Hypertriglyceridemia | 1 | 2007 | 316 | 0.010 |
Why?
|
Menstruation | 1 | 2005 | 307 | 0.010 |
Why?
|
Homeostasis | 1 | 2014 | 3306 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8624 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2019 | 7850 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2007 | 1343 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9585 | 0.010 |
Why?
|
Thorax | 1 | 2005 | 553 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2023 | 11891 | 0.010 |
Why?
|
DNA, Mitochondrial | 1 | 2007 | 858 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1114 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5305 | 0.010 |
Why?
|
Ovary | 1 | 2005 | 958 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8056 | 0.010 |
Why?
|
Anthropometry | 1 | 2005 | 1348 | 0.010 |
Why?
|
Transcription Factors | 1 | 2019 | 12103 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6771 | 0.010 |
Why?
|
Energy Intake | 1 | 2007 | 2129 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9411 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7475 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11903 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13502 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 6965 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 58995 | 0.010 |
Why?
|
Mice | 1 | 2021 | 81208 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 29658 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7806 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36290 | 0.010 |
Why?
|
Bone Density | 1 | 2005 | 3534 | 0.010 |
Why?
|
Animals | 1 | 2021 | 167963 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2005 | 14495 | 0.010 |
Why?
|
Neoplasms | 1 | 2017 | 22072 | 0.000 |
Why?
|